Nuwellis, Inc. ( (NUWE) ) has released its Q3 earnings. Here is a breakdown of the information Nuwellis, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nuwellis, Inc. is a medical technology company focused on advancing precision fluid management therapies for patients with cardiorenal conditions, utilizing its Aquadex SmartFlow system to improve patient outcomes. In its third quarter of 2025, Nuwellis reported a total revenue of $2.2 million, marking a 6% decrease year-over-year but a 29% increase sequentially. The company highlighted significant progress in its U.S. market, with increased consumable utilization and stronger console sales. Key developments include the launch of the 24-hour circuit and dual-lumen extended-length catheter, as well as the first Aquadex therapies delivered in a hospital-based outpatient setting under a new CMS code. Nuwellis also accelerated pediatric product development through an NIH-funded collaboration and a new U.S. patent. Despite a 30% increase in operating expenses due to investments in U.S. sales force and engineering, the company remains debt-free with $3.1 million in cash. Looking ahead, Nuwellis aims to strengthen its U.S.-driven business model and expand its leadership in precision fluid management across critical care and pediatrics.